Organization
Kyoto University Graduate School of Medicine
8 abstracts
Abstract
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).Org: Kumamoto University Hospital, Kurume University School of Medicine, Kitakyushu Municipal Medical Center, Wakayama Medical University, Wakayama, Japan, Internal Medicine III, Wakayama Medical University,
Abstract
Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer (JBCRG-M08; AMBER study).Org: Osaka University Hospital, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Nagoya University Hospital,
Abstract
The exploratory case-control study on prediction of immune checkpoint inhibitor-induced thyroiditis by human leukocyte antigen types.Org: Fukushima Medical University, School of Medicine, Kyoto University Graduate School of Medicine,
Abstract
A confirmatory trial of modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer with tumor diameter preoperatively estimated at 2 cm or less: Japan Clinical Oncology Group study, JCOG1101.Org: Toranomon Hospital, Tokyo Metropolitan Bokutoh Hospital, Radiation Therapy Center, Okinawa Chubu Hospital, Kagoshima University Hospital,
Abstract
Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.Org: Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Osaka International Cancer Institute, Osaka, Japan, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Kyorin University Faculty of Medicine,
Abstract
Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03.Org: Kanagawa Cancer Center, Matsuyama Red Cross Hospital, Nagoya University Graduate School of Medicine, Asahikawa Medical University Hospital, Yokohama City University Medical Center, Yokohama, Japan,
Abstract
First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).Org: Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tohoku University Graduate School of Medicine, Nippon Medical School Hospital, Niigata University Graduate School of Medical and Dental Sciences, Japanese Red Cross Okayama Hospital,
Abstract
ASSOCIATIONS BETWEEN ORGAN INVOLVEMENTS AND GENDER, ALLERGY, AND MALIGNANCY IN 166 PATIENTS WITH IGG4-RELATED DISEASEOrg: Kyoto University Graduate School of Medicine, Kobe University Graduate School of Medicine, Department of Rheumatology and Clinical Immunology, Kobe, Japan, Kansai Electric Power Hospital, Sapporo Medical University Hospital, Sapporo-Shi, Japan, Kansai Medical University Hospital,